Roswell Park Study Reveals How Venetoclax Boosts Immune Response to CAR T for Chronic Lymphocytic Leukemia
December 09, 2024
December 09, 2024
BUFFALO, New York, Dec. 9 (TNSres) -- The Roswell Park Comprehensive Cancer Center issued the following news release:
* * *
Dr. Matthew Cortese highlights new findings in talk at American Society of Hematology Annual Meeting
* * *
Research out of Roswell Park Comprehensive Cancer Center has shed light on how the drug venetoclax (brand name Venclexta) works synergistically with CAR T-cell immunotherapy to combat chronic lymphocytic leukemia (CL . . .
* * *
Dr. Matthew Cortese highlights new findings in talk at American Society of Hematology Annual Meeting
* * *
Research out of Roswell Park Comprehensive Cancer Center has shed light on how the drug venetoclax (brand name Venclexta) works synergistically with CAR T-cell immunotherapy to combat chronic lymphocytic leukemia (CL . . .